News · 26 weeks45-60%
2025-11-092026-05-03
Mix1690d
- Other8(50%)
- Insider4(25%)
- SEC Filings3(19%)
- Analyst1(6%)
Latest news
25 items- PRRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingIncludes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints Participation, retention, and treatment duration in the open-label extension (OLE) phase of the study is high and has resulted in continued glycemic benefit, concurrent with the reduction and/or discontinuation of background standard of care (SOC) therapies REDWOOD CITY, Calif., May 01, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypo
- PRRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingOral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that results from the Phase 3 sunRIZE study of ersodetug in congenital HI were accepted for an oral presentation at the Pediatric Endocrine Society (PES) Annual Meeting being held April 30-May 3, 2026, in San Francisco, CA. In addition to the previously reported topline results, the presentation will also include results from pre-s
- INSIDERSEC Form 4 filed by Evans Daron4 - Rezolute, Inc. (0001509261) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.SCHEDULE 13G/A - Rezolute, Inc. (0001509261) (Subject)
- ANALYSTRezolute upgraded by Wedbush with a new price targetWedbush upgraded Rezolute from Neutral to Outperform and set a new price target of $5.00
- SECRezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Rezolute, Inc. (0001509261) (Filer)
- PRRezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA MeetingREDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. In December 2025, the Company reported that sunRIZE demonstrated reductions from baseline in hypoglycemia events, but the study did not meet its primary endpoint because
- INSIDERChief Medical Officer Roberts Brian Kenneth covered exercise/tax liability with 11,439 shares, decreasing direct ownership by 4% to 296,913 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
- INSIDERCFO Evans Daron covered exercise/tax liability with 11,438 shares, decreasing direct ownership by 3% to 404,462 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
- INSIDERCEO Elam Nevan C covered exercise/tax liability with 27,618 shares, decreasing direct ownership by 4% to 613,501 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
- PRRezolute to Participate in the Citizens Life Sciences ConferenceREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Citizens Life Sciences Conference, taking place March 10-11, 2026, in Miami, FL. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Citizens representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hy
- SECSEC Form 10-Q filed by Rezolute Inc.10-Q - Rezolute, Inc. (0001509261) (Filer)
- SECRezolute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rezolute, Inc. (0001509261) (Filer)
- PRRezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business UpdateREDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025. Congenital Hyperinsulinism (HI) In December 2025, Rezolute reported topline results from sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI. The study did not meet its primary or key secondary endpoints. The study demonstrated reductions from baseline
- SECSEC Form SCHEDULE 13G filed by Rezolute Inc.SCHEDULE 13G - Rezolute, Inc. (0001509261) (Subject)
- PRRezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, taking place February 11-12, 2026 in New York. Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their Guggenheim representative. About Rezolute, Inc. Rezolute is a late-stage rare disease company focused on treating hypoglyc
- SECSEC Form SCHEDULE 13G filed by Rezolute Inc.SCHEDULE 13G - Rezolute, Inc. (0001509261) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Rezolute Inc.SCHEDULE 13G/A - Rezolute, Inc. (0001509261) (Subject)
- PRRezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor HyperinsulinismCompany believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today shared observations from the Phase 3 sunRIZE study in patients with congenital HI and provided details on the treatment of tumor HI patients with ersodetug under the Company's EAP. Congenital HI While sunRIZE did not meet its primary (hypoglycemi
- SECRezolute Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Rezolute, Inc. (0001509261) (Filer)
- SECSEC Form SCHEDULE 13G filed by Rezolute Inc.SCHEDULE 13G - Rezolute, Inc. (0001509261) (Subject)
- INSIDERDirector Hogenhuis Wladimir bought $9,548 worth of shares (5,650 units at $1.69), increasing direct ownership by 5% to 119,675 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
- INSIDERChief Medical Officer Roberts Brian Kenneth bought $47,600 worth of shares (28,000 units at $1.70), increasing direct ownership by 10% to 308,352 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
- INSIDERCFO Evans Daron bought $79,578 worth of shares (45,000 units at $1.77), increasing direct ownership by 11% to 415,900 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
- INSIDERCEO Elam Nevan C bought $50,880 worth of shares (32,000 units at $1.59), increasing direct ownership by 5% to 641,119 units (SEC Form 4)4 - Rezolute, Inc. (0001509261) (Issuer)
RZLT FAQ
6 questionsWhat does Rezolute Inc. do?
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio...Where does RZLT stock trade?
Rezolute Inc. (RZLT) is listed on NASDAQ.What sector and industry is RZLT in?
Rezolute Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about RZLT?
Rezolute Inc. has had 8 recent analyst actions on file. The most recent action was from Wedbush: Outperform with a $500.00 price target on 2026-03-25.What companies are similar to RZLT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare RZLT side-by-side with any of them on Quantisnow.How can I track RZLT on Quantisnow?
Quantisnow aggregates Rezolute Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RZLT to receive live email and push alerts on every new disclosure.